Sight Sciences (NASDAQ:SGHT) CTO Sells $23,858.82 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,051 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $7.82, for a total value of $23,858.82. Following the completion of the sale, the chief technology officer directly owned 1,920,804 shares of the company’s stock, valued at $15,020,687.28. This represents a 0.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

David Badawi also recently made the following trade(s):

• On Tuesday, January 6th, David Badawi sold 3,695 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total value of $27,638.60.
• On Friday, January 2nd, David Badawi sold 2,914 shares of Sight Sciences stock. The shares were sold at an average price of $7.43, for a total value of $21,651.02.

Sight Sciences Price Performance

Shares of NASDAQ SGHT traded down $0.24 during trading on Tuesday, hitting $7.47. 197,717 shares of the company were exchanged, compared to its average volume of 290,394. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $9.24. The company has a market cap of $394.94 million, a price-to-earnings ratio of -8.30 and a beta of 2.42. The firm’s fifty day moving average price is $7.52 and its 200 day moving average price is $5.13.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. The company had revenue of $12.54 million during the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. On average, sell-side analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Trading of Sight Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KCK LTD. purchased a new position in Sight Sciences in the 2nd quarter valued at about $18,069,000. Long Focus Capital Management LLC grew its holdings in shares of Sight Sciences by 1.3% during the third quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock worth $10,985,000 after buying an additional 41,797 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Sight Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock worth $6,559,000 after buying an additional 102,609 shares in the last quarter. Americana Partners LLC raised its position in shares of Sight Sciences by 42.4% in the third quarter. Americana Partners LLC now owns 1,229,819 shares of the company’s stock valued at $4,231,000 after buying an additional 365,901 shares during the last quarter. Finally, B Group Inc. lifted its stake in shares of Sight Sciences by 11.6% during the second quarter. B Group Inc. now owns 930,000 shares of the company’s stock valued at $3,841,000 after buying an additional 96,400 shares during the period. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Raymond James Financial set a $9.00 target price on Sight Sciences in a research report on Monday. Piper Sandler set a $9.00 price target on Sight Sciences in a research note on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Sight Sciences from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Finally, UBS Group upped their price target on shares of Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Sight Sciences has an average rating of “Hold” and an average target price of $8.30.

Key Stores Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade
• Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing
• Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (<1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. CEO sale filing CTO sale filing Other insider filings

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.